Staphylococcus aureus toxin lukg antigen epitope peptide and application thereof
By screening and identifying the antigenic epitope peptide and fusion protein of Staphylococcus aureus toxin LukG, the difficulty in developing a vaccine for MRSA infection was solved, and efficient and low-toxic prevention and treatment effects were achieved, which is suitable for the diagnosis and treatment of Staphylococcus aureus infection.
Patent Information
- Application Number
- CN202411510761.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-28
- Publication Date
- 2025-10-14
- Estimated Expiration
- 2044-10-28
AI Technical Summary
Existing technologies make it difficult to accurately screen and identify the immunodominant epitopes of Staphylococcus aureus toxin LukG involved in clinical MRSA infection, resulting in difficulties in developing vaccines for MRSA infection, and multidrug-resistant strains lead to poor efficacy of traditional antibiotic treatment.
Provided are antigenic epitope peptides of Staphylococcus aureus toxin LukG and fusion proteins thereof for use in preparing diagnostic reagents and drugs. A peptide segment with an amino acid sequence of SEQ ID NO: 40 is screened out through bioinformatics and immunological methods, coupled to a carrier protein, and combined with specific antibodies for diagnosis and treatment.
Highly effective and low-toxic prevention and treatment of Staphylococcus aureus infection has been achieved. The screened epitope peptides induced high levels of antibody response in animal models, significantly reduced infection colonization, and had extensive sequence conservation and immunogenicity.